On October 10, 2017 the CFDA published the “Review and approval system reform and support drug and medical device innovation” draft.

With the approval of this draft, manufacturers interested in marketing their Medical Devices in China will be able to include data from clinical trial carried out in their country of origin in the registration application.

In this way, it will be possible to facilitate foreign manufacturers registration process with the CFDA thus speeding up innovative Medical Devices circulation in China.

For more information: